MGC Pharmaceuticals Ltd (LSE: MXC, OTC: MGCLF, ASX: MXC) has strengthened its team with the appointment of Robert Clements, an experienced pharmaceutical industry executive, to the newly created position of Chief Commercial Officer.
This new role brings together the oversight and direction of all key business functions of the company, including business development, marketing and sales.
It also completes a restructuring of the main management positions of the European biopharmaceutical company specializing in the production and development of phytomedicines. The restructuring includes the establishment of a UK-based corporate team.
An expert in market development for rare and chronic diseases, Clements’ appointment will help advance MGC’s strategy and goal of becoming a leading provider of plant-derived medicines.
Meanwhile, Angela Marie Graham has taken up her post as the London-based company’s new chief financial officer.
“Restructuring of the management team”
MGC Co-Founder and Managing Director Roby Zomer said, “We are delighted to have Rob join the MGC Pharma team and look forward to working closely with him in this new role.
“His appointment follows that of Angela-Marie as the new London-based CFO and completes the restructuring of MGC Pharma’s management team.”
Clements brings with him more than 30 years of international experience in the pharmaceutical sector, having previously held several management positions in business development, commerce and marketing.
Most recently, he was Vice President of Business Development for the International Rare Drugs Division of Rare Sciences, a Netherlands-based international pharmaceutical services company specializing in the supply of drugs for rare diseases.
Clements said, “I am delighted to join MGC Pharma at this critical time for the business.
“The pharmaceutical industry relies on constant innovation and the company has proven to be creative and innovative in its approach to treating serious diseases and meeting patient needs for effective products.”